PERTEN

Información principal

  • Denominación comercial:
  • PERTEN 1% CREMA
  • Dosis:
  • 1 % (A7)
  • formulario farmacéutico:
  • CREMA
  • Usar para:
  • Humanos
  • Tipo de medicina:
  • medicamento alopático
  • Fabricado por:
  • MEYER PRODUCTOS TERAPEUTICOS S.A.

Documentos

Localización

  • Disponible en:
  • PERTEN 1% CREMA
    Venezuela
  • Idioma:
  • español

Otros datos

Estado

  • Fuente:
  • Instituto Nacional de Higiene - República Bolivariana de Venezuela
  • Estado de Autorización:
  • VIGENTE
  • Número de autorización:
  • E.F.37.330
  • Fecha de autorización:
  • 30-05-2008
  • última actualización:
  • 03-09-2018

Prospecto

Gobiemo

Bol¡variano

0 8 ? 9

Mi¡

sreno

del Poder

Popllar

5 iuN

?{[A

d í a

z o n a

a f e c t ¿ d ¿ .

sem¿nas,

acuéfdó

TiEGISTRO

NACION¡I¡

PRODUCTOS

r¡R¡ACEUTICOS

DFA.

ESrSER

¡'ÍEYEIR PRODUCTOS

TERAPETX¡ICOS

S,A,

De acuerdó

dictanen

JunLá Refis.¡a

p r o d u c r o s

Earmacéuticós,

en sesión

38 Acta

N"

9118

de fechá

3 0 / 0 5 / 2 O O g ,

se ap¡ueba

producto

?IRTEN 1*

cRn'¡\

Eolrc¡

SrrF-07-03t3.

r "

3 7 , 3 3 0 .

t ó

, ó

. , é

o . s p o

o é

. ó

" J

F¡rm:.éuti.ós,

¡é.ónside¡ació¡

€ x i q e n . i á .

cónpfónaso

de comuni.a¡

G¡enio ¡¡édi.o

s i q u i e n r e :

producto

aceprable

siquientes

c o n d i c i o n e s

fungicida.

I^fécciones

pó¡

hóngos

piel

PosóIoqía

(¡te.@¡da.Ia)

ApIiques.

suawcmcnte

Dur¿caó¡

t¡ataniento:

severidad

de la

i n f e c c i ó n .

solo

pá¡a

externo.

Evirar

c.ntactó

con 1os

olos.

e s t ;

pe¡i.do

de lácta.cia

cónsulre

su médicó

antes '1e

usar

este p¡oducto.

sintonas

persiste.

con e1

suspéndase

c.nsulte

á 1

nédi.o.

débe ser usadó én la

. , r :

Use cón

precaución

pacie^tes

lesio¡es

donde

e1 alcohól

N. ex.eda

dosis

¡ecomendada.

f l o r

q d r -

. - , d

q 1 '

d é ó d i

p , ó . p ó . i o

é . . ó .

cóntlaindicacionés

areigaa

compónéntes

de 1a fófhLl¿.

.ELIMINEMOS

LA RUBEOLA

DE UNA

SOLA

Y PARA

SIEMPRE'

sle¡o del Poder

Pop!

REGISTRO

NACIONAI!

DE IRODUCIOS

E¡RMACEUTICOS

asigna

p¡oducto

p€¡iodó

validez

renrativo

(02)

¿ñOS

EIJBO COI,APSIBI]E

¡IUMINIO

REVESTIMIE¡IIO

INTERNO

E?OXIDO

TAIA

ROSCA

?orrPRo?Ir¡ENo

cor¡m

Ro{ro,

comp¡omiso

¡emiri¡

r " d "

d - . o n

é d o

o o ¿ ó

segundo aÁó

perlodo

de v¿lidez

a s i g n a d o ,

.rmacenadó

b¿jó

condi.i.nes

clináti.as

<le

v e n e z u e l á

1 : 1 0 " c ! 2 " c / l 0 t 1 5 t H R ) .

"

t . ; m

" . b < ¡ 9

, - .

ó p . o o é . : o n

¡eglstro

sanltario

c€¡tificado

Buénas

Prácticas

Manufactu¡¿ original

vigenté,

o en su defecro

.opia

c o m p u l -

Co.reqi¡

Le\tos

esi!.he

etiqueta

según nódelos

a ¡ e r o s /

ojos,

está

enrbarazada

pe¡iódó

lactancia

coñsulte

nédi.ó

antes

u s a ¡

este

prodDcto.

1os sintonas

pe.sisten

.ón

e1 uso

de este

suspendase

consulre

médic..

No debe ser

Us€

plecaución

pácientes.on

lesiónés

donde

e1 alcohól

puorera

se¡

1 Í 1 r a n t e .

e¡ceda la.losis

r e c ó m € n d a d a .

a g r e q a n d o . ó n d i c i o n e s

p¡ospccto

lnter.o

3egún

nodelo

3 . e n ¡ ,

¡est¡lc.iónes

uso aprobadas

pói

¡onb¡e de1

produ.tó

és:

Pe¡ten

c¡ena Tópica

lós

fiñes

estricro

cunptimiento

a¡riculo

€o

d e 1

publicado

en Gaceta oficiaL

No. 4,532 extraordiñá¡io

de fecha

nay.

1993,

informa

está¡

obliqados

r¿ runté

Revisora

Fa¡macéuticos, 1¿

fecha

.uaI

inicie

cómer.ialización

D ¡ i n e r

lote

elabo¡ado,

mane¡a que

lós

funcionarios

a c r e d i t a d ó s

lnstituto

Naciónér

d.é Ni

$Ráfa€1

Ranqe1,,,

p u e d a n

p¡ócede¡

cápt¿¡

nuest¡as

có¡respo.dientes

en el

p r o p i o

sitio

fabricá.ión,

dist¡ibución

casó

1 o s

p¡oductos

lnportadós.

incumpliniento

mencionadó

ó . ¡ o c d o

" o o f

p . . o

, ó .

,ELIIúINE]VOS

RUBEOLA

SOLAVEZY

PARASIEMPRE'

Gobi€mo

Bolivariano

fi4in¡steÍo

Poder

Popular

REGISTRO

¡¡ACIONAI,

PRODUC1IcS

FAR¡'ACEUTICOS

Transcur¡ido

dicho

lapso

queda

usted

cumplir

condiciónés

usó

ap¡obadó

producto,

obligación

bajo

cuarés

f u e

a¡¡¡tacÉttttcos

,ELIMINEMOS

!A RUBEOLAOE

SOLA

Y PARA

SIEMPRE"

lt>

frr*rs

".!!l

15-11-2018

Drug Safety Update , Noviembre 2018

MHRA , 14 de noviembre de 2018 Hidroclorotiazida: riesgo de cáncer de piel no melanoma Sildenafil: hipertensión pulmonar persistente del recién nacido Fluoroquinolonas: aneurisma y disección aórtica

REDCIMLAC - Red de Centros de Información de Medicamentos de Latinoamérica y el Caribe

8-11-2018

Identifican un nuevo mecanismo molecular responsable del envejecimiento del corazón

Identifican un nuevo mecanismo molecular responsable del envejecimiento del corazón

Un estudio dirigido por Marisol Ruiz-Meana, investigadora principal del grupo de Enfermedades Cardiovasculares del Vall d’Hebron Institut de Recerca (VHIR) que dirige David García-Dorado, en el que ha participado el Grupo de Química de Proteínas del Centro Nacional de Investigación Cardiovascular (CNIC), ambos pertenecientes al CIBERCV, ha descubierto que las alteraciones funcionales de las células […]

Cuba - infomed - Red de Salud de Cuba

5-7-2018

Recall of valsartan blood pressure medicine

Recall of valsartan blood pressure medicine

Impurities that could potentially be harmful to health have been found in variants of medicines containing the active substance valsartan. The medicine is used to treat hypertension and heart failure. Patients treated with these medicines are therefore advised to contact their doctor as soon as possible to be switched to another type of medicine.

Danish Medicines Agency

4-6-2018

Hospira Issues a Voluntary Nationwide Recall for Two Lots of Naloxone Hydrochloride Injection, USP, in the Carpuject™ Syringe System due to the Potential Presence of Particulate Matter

Hospira Issues a Voluntary Nationwide Recall for Two Lots of Naloxone Hydrochloride Injection, USP, in the Carpuject™ Syringe System due to the Potential Presence of Particulate Matter

Hospira, Inc., a Pfizer company, is voluntarily recalling lots 72680LL and 76510LL of Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL, Carpuject Single-use cartridge syringe system (NDC 0409-1782-69), to the hospital/institution level due to the potential presence of embedded and loose particulate matter on the syringe plunger.

FDA - U.S. Food and Drug Administration

4-6-2018

Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL in the Carpuject™ Single-use Cartridge Syringe System   by Hospira: Recall - Due to the Potential Presence of Particulate Matter

Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL in the Carpuject™ Single-use Cartridge Syringe System by Hospira: Recall - Due to the Potential Presence of Particulate Matter

The patient has a low likelihood of experiencing adverse events ranging from local irritation, allergic reactions, phlebitis, end-organ granuloma, tissue ischemia, pulmonary emboli, pulmonary dysfunction, pulmonary infarction, and toxicity.

FDA - U.S. Food and Drug Administration

25-5-2018

Orphan designation:  Treprostinil sodium,  for the: Treatment of chronic thromboembolic pulmonary hypertension

Orphan designation: Treprostinil sodium, for the: Treatment of chronic thromboembolic pulmonary hypertension

On 8 February 2013, orphan designation (EU/3/13/1103) was granted by the European Commission to SciPharm S.a.r.L, Luxembourg, for treprostinil sodium for the treatment of chronic thromboembolic pulmonary hypertension.

Europe - EMA - European Medicines Agency

24-5-2018

FDA Approves Semintra, the First FDA-approved Animal Drug for the Control of Systemic Hypertension in Cats

FDA Approves Semintra, the First FDA-approved Animal Drug for the Control of Systemic Hypertension in Cats

The FDA has approved Semintra (telmisartan oral solution), the first FDA-approved animal drug to control systemic hypertension in cats. Semintra is an oral solution administered either directly into the cat’s mouth or on top of a small amount of food.

FDA - U.S. Food and Drug Administration

13-11-2018

EU/3/17/1836 (Zogenix GmbH)

EU/3/17/1836 (Zogenix GmbH)

EU/3/17/1836 (Active substance: Fenfluramine hydrochloride) - Transfer of orphan designation - Commission Decision (2018)7576 of Tue, 13 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/233/16/T/01

Europe -DG Health and Food Safety

13-11-2018

EU/3/13/1219 (Zogenix GmbH)

EU/3/13/1219 (Zogenix GmbH)

EU/3/13/1219 (Active substance: Fenfluramine hydrochloride) - Transfer of orphan designation - Commission Decision (2018)7575 of Tue, 13 Nov 2018 European Medicines Agency (EMA) procedure number: EMA/OD/140/13/T/01

Europe -DG Health and Food Safety

1-11-2018

Dexdomitor (Orion Corporation)

Dexdomitor (Orion Corporation)

Dexdomitor (Active substance: dexmedetomidine hydrochloride) - Centralised - Yearly update - Commission Decision (2018)7380 of Thu, 01 Nov 2018

Europe -DG Health and Food Safety

31-10-2018

Evista (Daiichi Sankyo Europe GmbH)

Evista (Daiichi Sankyo Europe GmbH)

Evista (Active substance: Raloxifene hydrochloride) - Centralised - Yearly update - Commission Decision (2018)7342 of Wed, 31 Oct 2018

Europe -DG Health and Food Safety

26-9-2018

Sileo (Orion Corporation)

Sileo (Orion Corporation)

Sileo (Active substance: Dexmedetomidine hydrochloride) - Centralised - Yearly update - Commission Decision (2018)6325 of Wed, 26 Sep 2018

Europe -DG Health and Food Safety

10-8-2018

Brinavess (Correvio)

Brinavess (Correvio)

Brinavess (Active substance: vernakalant hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5523 of Fri, 10 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1215/T/31

Europe -DG Health and Food Safety

30-7-2018

Segluromet (Merck Sharp and Dohme B.V.)

Segluromet (Merck Sharp and Dohme B.V.)

Segluromet (Active substance: ertugliflozin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5103 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4314/T/2

Europe -DG Health and Food Safety

30-7-2018

Ceplene (Noventia Pharma Srl)

Ceplene (Noventia Pharma Srl)

Ceplene (Active substance: Histamine dihydrochloride) - Centralised - Renewal - Commission Decision (2018)5116 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/796/R/36

Europe -DG Health and Food Safety

23-7-2018

Optruma (Eli Lilly Nederland B.V.)

Optruma (Eli Lilly Nederland B.V.)

Optruma (Active substance: Raloxifene hydrochloride) - Centralised - Yearly update - Commission Decision (2018)4893 of Mon, 23 Jul 2018

Europe -DG Health and Food Safety

12-7-2018

Econor (Elanco Europe Ltd)

Econor (Elanco Europe Ltd)

Econor (Active substance: Valnemulin hydrochloride) - Centralised - Yearly update - Commission Decision (2018)4580 of Thu, 12 Jul 2018

Europe -DG Health and Food Safety

11-7-2018

Ariclaim (Eli Lilly Nederland B.V.)

Ariclaim (Eli Lilly Nederland B.V.)

Ariclaim (Active substance: duloxetine hydrochloride) - Centralised - Withdrawal - Commission Decision (2018)4515 of Wed, 11 Jul 2018

Europe -DG Health and Food Safety

5-7-2018

Scientific guideline:  Draft pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance, draft: consultation open

Scientific guideline: Draft pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml product-specific bioequivalence guidance, draft: consultation open

This document provides product-specific guidance on the demonstration of the bioequivalence of pegylated liposomal doxorubicin hydrochloride concentrate for solution 2 mg/ml.

Europe - EMA - European Medicines Agency

3-7-2018

Efficib (Merck Sharp and Dohme B.V.)

Efficib (Merck Sharp and Dohme B.V.)

Efficib (Active substance: sitagliptin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4254 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/896/T/90

Europe -DG Health and Food Safety

3-7-2018

Ristfor (Merck Sharp and Dohme B.V.)

Ristfor (Merck Sharp and Dohme B.V.)

Ristfor (Active substance: sitagliptin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4249 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1235/T/77

Europe -DG Health and Food Safety

3-7-2018

Velmetia (Merck Sharp and Dohme B.V.)

Velmetia (Merck Sharp and Dohme B.V.)

Velmetia (Active substance: sitagliptin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4252 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/862/T/93

Europe -DG Health and Food Safety

3-7-2018

Janumet (Merck Sharp and Dohme B.V.)

Janumet (Merck Sharp and Dohme B.V.)

Janumet (Active substance: sitagliptin / metformin hydrochloride) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018) 4251 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/861/T/90

Europe -DG Health and Food Safety

29-6-2018

EU/3/18/2028 (BioCryst UK Ltd)

EU/3/18/2028 (BioCryst UK Ltd)

EU/3/18/2028 (Active substance: (R)-1-(3-(aminomethyl) phenyl)-N-(5-((3-cyanophenyl)(cyclopropylmethylamino)methyl)-2-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide dihydrochloride) - Orphan designation - Commission Decision (2018)4173 of Fri, 29 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/003/18

Europe -DG Health and Food Safety

14-6-2018

Kuvan (BioMarin International Limited)

Kuvan (BioMarin International Limited)

Kuvan (Active substance: sapropterin dihydrochloride) - Centralised - Yearly update - Commission Decision (2018)3859 of Thu, 14 Jun 2018

Europe -DG Health and Food Safety

12-6-2018

EU/3/10/811 (Celgene Europe B.V.)

EU/3/10/811 (Celgene Europe B.V.)

EU/3/10/811 (Active substance: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate) - Transfer of orphan designation - Commission Decision (2018)3809 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/092/10/T/03

Europe -DG Health and Food Safety

12-6-2018

EU/3/10/810 (Celgene Europe B.V.)

EU/3/10/810 (Celgene Europe B.V.)

EU/3/10/810 (Active substance: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate) - Transfer of orphan designation - Commission Decision (2018)3808 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/084/10/T/03

Europe -DG Health and Food Safety

12-6-2018

EU/3/10/794 (Celgene Europe B.V.)

EU/3/10/794 (Celgene Europe B.V.)

EU/3/10/794 (Active substance: N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino] benzenesulfonamide dihydrochloride monohydrate) - Transfer of orphan designation - Commission Decision (2018)3803 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/069/10/T/03

Europe -DG Health and Food Safety

12-6-2018

EU/3/11/888 (Gilead Sciences Ireland UC)

EU/3/11/888 (Gilead Sciences Ireland UC)

EU/3/11/888 (Active substance: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt) - Transfer of orphan designation - Commission Decision (2018)3802 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/152/10/T/03

Europe -DG Health and Food Safety

12-6-2018

EU/3/11/887 (Gilead Sciences Ireland UC)

EU/3/11/887 (Gilead Sciences Ireland UC)

EU/3/11/887 (Active substance: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt) - Transfer of orphan designation - Commission Decision (2018)3801 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/020/11/T/03

Europe -DG Health and Food Safety

12-6-2018

EU/3/11/886 (Gilead Sciences Ireland UC)

EU/3/11/886 (Gilead Sciences Ireland UC)

EU/3/11/886 (Active substance: N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide, dihydrochloride salt) - Transfer of orphan designation - Commission Decision (2018)3799 of Tue, 12 Jun 2018 European Medicines Agency (EMA) procedure number: EMA/OD/019/11/T/03

Europe -DG Health and Food Safety

30-5-2018

Eviplera (Gilead Sciences Ireland UC)

Eviplera (Gilead Sciences Ireland UC)

Eviplera (Active substance: emtricitabine / rilpivirine (as hydrochloride) / tenofovir disoproxil (as fumarate)) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3453 of Wed, 30 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2312/T/91

Europe -DG Health and Food Safety

30-5-2018

Vokanamet (Janssen-Cilag International NV)

Vokanamet (Janssen-Cilag International NV)

Vokanamet (Active substance: canagliflozin / metformin hydrochloride) - Centralised - Yearly update - Commission Decision (2018)3463 of Wed, 30 May 2018

Europe -DG Health and Food Safety

29-5-2018

EU/3/18/2017 (Spedding Research Solutions SAS)

EU/3/18/2017 (Spedding Research Solutions SAS)

EU/3/18/2017 (Active substance: Ambroxol hydrochloride) - Orphan designation - Commission Decision (2018)3384 of Tue, 29 May 2018 European Medicines Agency (EMA) procedure number: EMA/OD/236/17

Europe -DG Health and Food Safety

29-5-2018

Osurnia (Elanco Europe Ltd)

Osurnia (Elanco Europe Ltd)

Osurnia (Active substance: terbinafine / florfenicol / betamethasone acetate) - Centralised - Yearly update - Commission Decision (2018)3406 of Tue, 29 May 2018

Europe -DG Health and Food Safety

24-5-2018

Want a #HealthyHeart? Get moving! Here are some ways you can #MoveWithHeart today!  http://bit.ly/2II1XR2  #MoveInMay #HypertensionMonthpic.twitter.com/3teHPIlA40

Want a #HealthyHeart? Get moving! Here are some ways you can #MoveWithHeart today! http://bit.ly/2II1XR2  #MoveInMay #HypertensionMonthpic.twitter.com/3teHPIlA40

Want a #HealthyHeart? Get moving! Here are some ways you can #MoveWithHeart today! http://bit.ly/2II1XR2  #MoveInMay #HypertensionMonth pic.twitter.com/3teHPIlA40

FDA - U.S. Food and Drug Administration

24-5-2018

Velmetia (Merck Sharp and Dohme Limited)

Velmetia (Merck Sharp and Dohme Limited)

Velmetia (Active substance: sitagliptin / metformin hydrochloride) - PSUSA - Modification - Commission Decision (2018)3261 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/2003/201708

Europe -DG Health and Food Safety

24-5-2018

Ristfor (Merck Sharp and Dohme Limited)

Ristfor (Merck Sharp and Dohme Limited)

Ristfor (Active substance: sitagliptin / metformin hydrochloride) - PSUSA - Modification - Commission Decision (2018)3262 of Thu, 24 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/2003/201708

Europe -DG Health and Food Safety